Independent register of U.S. FDA drug recalls · updated Oct 10, 2026
RxRecalls Get alerts
Class II · Moderate risk Ongoing Initiated Sep 16, 2024 (2 years ago)

Refresh LACRI-LUBE

Class II — Moderate risk. May cause temporary or reversible harm; serious harm unlikely.

Why it was recalled

Lack of Assurance of Sterility: The impacted lots may contain a breach in the tube seal.

Cause type: Sterility / contamination

A product that must be sterile could not be assured sterile, or was contaminated. A top reason for injectables, eye drops and IV products - loss of sterility assurance can lead to serious infections. All sterility / contamination recalls.

What was recalled

Refresh LACRI-LUBE, (42.5% Mineral Oil, 57.3% White Petrolatum) Lubricant Eye Ointment, Net wt, 0.12 oz (3.5g) Tube, Distributed by: Allergen, an AbbVie company, Madison, NJ 07940, UPC code: 300230312042

Category: Eye Drops & Ophthalmic

Recalling firm
AbbVie Inc.
Origin
IL, United States
Initiated by
Voluntary: Firm initiated
FDA recall number
D-0665-2024 · FDA notice

Check, then ask. Class II means harm is possible but usually temporary or reversible. Find the lot number on your package; if it matches, ask your pharmacist about a replacement. Do not simply stop a prescribed medication on your own - the gap can be riskier than the recall.

Other recalls by AbbVie Inc.

All 2024 recalls
Class II · Moderate risk

Refresh P.M.

Lack of Assurance of Sterility: The impacted lots may contain a breach in the tube seal.

Ongoing Sterility / contamination AbbVie Inc. D-0664-2024
Class III · Low risk

Synthroid

Labeling: Wrong Barcode- One (1) of every forty (40) unit dose blister will contain incorrect barcode information that causes a 125mcg unit dose is scanned as 200mcg unit dose.

Ongoing Labeling / mix-up AbbVie Inc. NDC 0074-7068-11 D-0088-2024
Class III · Low risk

Ultane (sevoflurane)

Defective container: presence of a hole in the liners of the caps covering the product bottle, introducing possibility of leakage.

Terminated Packaging defect AbbVie Inc. NDC 0074-4456-51 D-0412-2018

Other sterility / contamination recalls from 2024

All sterility / contamination recalls
Class II · Moderate risk

ketamine inj 50 mg per 1 mL

Lack of Assurance of Sterility: The tamper-evident seal on several of the syringes are not attached upon receipt of shipment.

Terminated Sterility / contamination Hikma Injectables USA Inc NDC 63037-137-25 D-0173-2025